Dravet Syndrome affects the entire family.

Although seizures caused by Dravet syndrome are often resistant to seizure medications, researchers continue studying investigational drugs to determine if they have the potential to more effectively control seizures.

**Momentum 1** is a clinical research study evaluating the safety and efficacy of an investigational drug to potentially help manage the number of seizures in patients with Dravet syndrome when added to their current epilepsy medication. ("Investigational" means the drug is experimental and has not been approved for use in the area being studied.)

If your child or loved one with Dravet syndrome is experiencing uncontrolled seizures, see if they may be eligible to participate in the **Momentum 1** clinical research study.

For more information:
www.Momentum1Study.org
Who Qualifies for the Momentum 1 Study?

Your child or loved one may qualify for the Momentum 1 Study if they:

- Have a diagnosis of epilepsy with Dravet syndrome
- Are at least 2 years of age

"Other eligibility criteria may apply"

Why Participate in the Momentum 1 Study?

Taking part in a study offers the opportunity to possibly progress medical research. The information gained from this study may help to understand more about the investigational drug and may help to treat those with Dravet syndrome better in the future.

What is Involved in the Momentum 1 Study?

The Momentum 1 Study will compare the safety and efficacy of a new investigational drug for Dravet syndrome called lorcaserin to placebo (a sugar pill) when added to your child or loved one’s current epilepsy medication.

The Momentum 1 Study Breakdown

**Screening (4 weeks)**
During this period, the patient will meet with the study doctor to determine if they qualify to participate in the study.

**Treatment (26 weeks total)**
During the first 14 weeks of treatment, your child or loved one will receive either the investigational drug or a placebo in addition to their current epilepsy medication.

During the second 12 weeks of treatment (Extension Phase) all eligible patients will receive the investigational drug.

**Follow-up (4 weeks after last dosage)**
This visit will be a final safety follow-up visit for patients that do not continue into the extended access program.

**Travel reimbursement**
If your child or loved one qualifies and participates, they may be eligible to receive reimbursement for study-related travel expenses.

After this clinical study, your child or loved one may be able to join an extended access program in an effort to continue providing lorcaserin until the product is approved. This will require an additional consent.

Source: clinicaltrials.gov